Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Wei, Zihui ^a   Spizzo, Iresha ^a   Diep, Henry ^a   Drummond, Grant R ^a   Widdop, Robert E ^a   Vinh, Antony ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN II; IL17A PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD CELL; BRAIN CELL; BRAIN TISSUE; CELL INFILTRATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HYPERTENSION; KIDNEY PARENCHYMA; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROTEIN ANALYSIS; SPLEEN CELL; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; METABOLISM; PATHOLOGY; VASCULAR DISEASE;

MUS;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; HUMANS; HYPERTENSION; INTERLEUKIN-17; INTERLEUKIN-4; MICE; PHENOTYPE; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 84917690491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114895     Document Type: Article

References (47)

1. WHO (2013) Cardiovascular diseases Facts Sheet. Switzerland.
2. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, et al. (2013) Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 62: 691-697.
3. Judd E, Calhoun DA (2014) Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens.
4. Harrison DG, Vinh A, Lob H, Madhur MS (2010) Role of the adaptive immune system in hypertension. Curr Opin Pharm 10: 203-207.
5. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, et al. (2010) Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Renal Physiol 298: R1089-R1097.
6. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, et al. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460.
7. Abbas A, Lichtman A, Pillai S (2011) Cellular and molecular immunology. Philadelphia, PA: Elsevier Saunders.
8. D'Acquisto F, Crompton T (2011) CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response? Biochem Pharmacol 82: 333-340.
9. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440.
10. Lourenc¸o EV, La Cava A (2009) Cytokines in Systemic Lupus Erythermatosus. Curr Mol Med 9: 242-254.
11. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. New Engl J Med 365: 2205-2219.
12. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2: 108-115.
13. Iwamoto T, Okamoto H, Toyama Y, Momohara S (2008) Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 275: 4448-4455.
14. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, et al. (2012) Longterm Retention of Tumor Necrosis Factor-alpha Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. J Rheumatol 39: 1179-1184.
15. Kaly L, Rosner I (2012) Tocilizumab - A novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 26: 157-165.
16. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, et al. (2010) Inhibition and Genetic Ablation of the B7/CD28 T-Cell Costimulation Axis Prevents Experimental Hypertension. Circulation 122: 2529-2537.
17. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, et al. (2003) Imbalance of T-Cell Subsets in Angiotensin II-Infused Hypertensive Rats With Kidney Injury. Hypertension 42: 31-38.
18. Chan CT, Moore JP, Budzyn K, Guida E, Diep H, et al. (2012) Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension 60: 1207-1212.
19. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, et al. (2010) Interleukin 17 Promotes Angiotensin II-Induced Hypertension and Vascular Dysfunction. Hypertension 55: 500-507.
20. Mirkov I, Glamoclija J, Stosic-Grujicic S, Zolotarevski L, Kataranovski D, et al. (2012) Differential strain-related tissue immune response to sublethal systemic Aspergillus fumigatus infection in mice. Acta Pathol Microbiol Immunol Scand C 121: 211-220.
21. Choi YK, Yoon BI, Won YS, Lee CH, Hyun BH, et al. (2003) Cytokine responses in mice infected with Clonorchis sinensis. Parasitol Res 91: 87-93.
22. Taherzadeh Z, VanBavel E, de Vos J, Matlung H, van Montfrans G, et al. (2010) Strain-dependent susceptibility for hypertension in mice resides in the natural killer gene complex. Am J Physiol Heart Circ Physiol 298: 82.
23. Gutkowska J, Granger JP, Lamarca BB, Danalache BA, Wang D, et al. (2011) Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade. J Hypertens 29: 1203-1212.
24. Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, et al. (2010) Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 56: 643-649.
25. Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, et al. (2012) Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One 7: e40065.
26. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, et al. (2008) Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 295: F515-F524.
27. De Miguel C, Das S, Lund H, Mattson DL (2010) T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 298: R1136-R1142.
28. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, et al. (2002) Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-201.
29. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, et al. (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57: 469-476.
30. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27: 1128-1135.
31. Wahlstrom J, Katchar K, Wigzell H, Olerup O, Eklund A, et al. (2001) Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood Tcells in sarcoidosis. Am J Respir Crit Care Med 163: 115-121.
32. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B (1994) Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J 8: 1055-1060.
33. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91: 3652-3656.
34. Fernandez EJ, Lolis E (2002) Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42: 469-499.
35. Hilgers KF, Hartner A, Porst M, Mai M, Wittmann M, et al. (2000) Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int 58: 2408-2419.
36. Owen JL, Lopez DM, Grosso JF, Guthrie KM, Herbert LM, et al. (2005) The expression of CCL2 by T lymphocytes of mammary tumor bearers: role of tumor-derived factors. Cell Immunol 235: 122-135.
37. Owen JL, Torroella-Kouri M, Handel-Fernandez ME, Iragavarapu-Charyulu V (2007) GM-CSF upregulates the expression of CCL2 by T lymphocytes in mammary tumor-bearing mice. Int J Mol Med 20: 129-136.
38. Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K (1997) The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol 182: 106-114.
39. Bush E, Maeda N, Kuziel WA, Dawson TC, Wilcox JN, et al. (2000) CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension 36: 360-363.
40. Drummond GR, Selemidis S, Griendling KK, Sobey CG (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471.
41. Vaziri ND, Wang XQ, Oveisi F, Rad B (2000) Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36: 142-146.
42. Lim YC, Garcia-Cardena G, Allport JR, Zervoglos M, Connolly AJ, et al. (2003) Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. Am J Pathol 162: 1591-1601.
43. De Miguel C, Guo C, Lund H, Feng D, Mattson D (2011) Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. Am J Physiol Renal Physiol 300: 42.
44. Shang F, Wang J, Liu X, Li J, Zheng Q, et al. (2012) Involvement of reactive oxygen species and JNK in increased expression of MCP-1 and infiltration of inflammatory cells in pressure-overloaded rat hearts. Mol Med Report 5: 1491-1496.
45. Chen XL, Zhang Q, Zhao R, Medford RM (2004) Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 286: H1001-H1007.
46. Catt KJ, Cran E, Zimmet PZ, Best JB, Cain MD, et al. (1971) Angiotensin II blood-levels in human hypertension. Lancet 1: 459-464.
47. Catt KJ, Cain MD, Coghlan JP, Zimmet PZ, Cran E, et al. (1970) Metabolism and blood levels of angiotensin II in normal subjects, renal disease, and essential hypertension. Circul Res 27: Suppl 2: 177+.